The global drug and gene delivery devices market size is calculated at USD 792.67 million in 2025 and is forecasted to reach around USD 1738.73 million by 2034, accelerating at a CAGR of 9.12% from 2025 to 2034. The North America drug and gene delivery devices market size surpassed USD 293.84 million in 2024 and is expanding at a CAGR of 9.13% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Drug and Gene Delivery Devices Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Drug and Gene Delivery Devices Market, by Delivery Type,
8.1.1. Oral
8.1.1.1. Market Revenue and Forecast
8.1.2. Ocular
8.1.2.1. Market Revenue and Forecast
8.1.3. Inhalation
8.1.3.1. Market Revenue and Forecast
8.1.4. Nasal
8.1.4.1. Market Revenue and Forecast
8.1.5. Injectable
8.1.5.1. Market Revenue and Forecast
8.1.6. Transdermal
8.1.6.1. Market Revenue and Forecast
8.1.7. Topical
8.1.7.1. Market Revenue and Forecast
9.1. Drug and Gene Delivery Devices Market, by Method,
9.1.1. In Situ
9.1.1.1. Market Revenue and Forecast
9.1.2. Ex Vivo
9.1.2.1. Market Revenue and Forecast
10.1. Drug and Gene Delivery Devices Market, by Vector,
10.1.1. Viral Vector
10.1.1.1. Market Revenue and Forecast
10.1.2. Non-Viral Vector
10.1.2.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Delivery
11.1.2. Market Revenue and Forecast, by Method
11.1.3. Market Revenue and Forecast, by Vector
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Delivery
11.1.4.2. Market Revenue and Forecast, by Method
11.1.4.3. Market Revenue and Forecast, by Vector
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Delivery
11.1.5.2. Market Revenue and Forecast, by Method
11.1.5.3. Market Revenue and Forecast, by Vector
11.2. Europe
11.2.1. Market Revenue and Forecast, by Delivery
11.2.2. Market Revenue and Forecast, by Method
11.2.3. Market Revenue and Forecast, by Vector
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Delivery
11.2.4.2. Market Revenue and Forecast, by Method
11.2.4.3. Market Revenue and Forecast, by Vector
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Delivery
11.2.5.2. Market Revenue and Forecast, by Method
11.2.5.3. Market Revenue and Forecast, by Vector
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Delivery
11.2.6.2. Market Revenue and Forecast, by Method
11.2.6.3. Market Revenue and Forecast, by Vector
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Delivery
11.2.7.2. Market Revenue and Forecast, by Method
11.2.7.3. Market Revenue and Forecast, by Vector
11.3. APAC
11.3.1. Market Revenue and Forecast, by Delivery
11.3.2. Market Revenue and Forecast, by Method
11.3.3. Market Revenue and Forecast, by Vector
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Delivery
11.3.4.2. Market Revenue and Forecast, by Method
11.3.4.3. Market Revenue and Forecast, by Vector
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Delivery
11.3.5.2. Market Revenue and Forecast, by Method
11.3.5.3. Market Revenue and Forecast, by Vector
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Delivery
11.3.6.2. Market Revenue and Forecast, by Method
11.3.6.3. Market Revenue and Forecast, by Vector
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Delivery
11.3.7.2. Market Revenue and Forecast, by Method
11.3.7.3. Market Revenue and Forecast, by Vector
11.4. MEA
11.4.1. Market Revenue and Forecast, by Delivery
11.4.2. Market Revenue and Forecast, by Method
11.4.3. Market Revenue and Forecast, by Vector
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Delivery
11.4.4.2. Market Revenue and Forecast, by Method
11.4.4.3. Market Revenue and Forecast, by Vector
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Delivery
11.4.5.2. Market Revenue and Forecast, by Method
11.4.5.3. Market Revenue and Forecast, by Vector
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Delivery
11.4.6.2. Market Revenue and Forecast, by Method
11.4.6.3. Market Revenue and Forecast, by Vector
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Delivery
11.4.7.2. Market Revenue and Forecast, by Method
11.4.7.3. Market Revenue and Forecast, by Vector
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Delivery
11.5.2. Market Revenue and Forecast, by Method
11.5.3. Market Revenue and Forecast, by Vector
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Delivery
11.5.4.2. Market Revenue and Forecast, by Method
11.5.4.3. Market Revenue and Forecast, by Vector
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Delivery
11.5.5.2. Market Revenue and Forecast, by Method
11.5.5.3. Market Revenue and Forecast, by Vector
12.1. Pfizer, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. F. Hoffmann-La Roche Ltd
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Johnson and Johnson Private Ltd
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Novartis AG
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Becton, Dickinson and Company
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Uniqure NV
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample